Advertisement
Advertisement
U.S. markets open in 7 hours 42 minutes
Advertisement
Advertisement
Advertisement
Advertisement

AMRN Jun 2023 3.000 put

OPR - OPR Delayed Price. Currency in USD
1.75000.0000 (0.00%)
As of 12:43PM EST. Market open.
Advertisement
Full screen
Previous Close1.7500
Open1.7500
Bid0.0000
Ask0.0000
Strike3.00
Expire Date2023-06-16
Day's Range1.7500 - 1.7500
Contract RangeN/A
Volume1
Open InterestN/A
  • Barrons.com

    Amarin and ViewRay Stock See Action From Activist Investors

    Sarissa Capital is pushing to get a slate of directors on the board of pharmaceutical firm Amarin. Hudson Executive disclosed a large stake in radiation-treatment equipment maker ViewRay.

  • GlobeNewswire

    Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand

    Marks 7th Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets Since 2022DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Medsafe in New Zealand has granted approval to VAZKEPA (icosapent ethyl) to reduce the risk of cardiovascular (CV) events in adult statin-treated patients with high CV risk with elevated triglycerides. Cardiovascular disease is a significant health issue for people li

  • GlobeNewswire

    Amarin to Present at SVB Securities Global Biopharma Conference

    DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the SVB Securities Global Biopharma Conference. SVB Securities Global Biopharma Conference (February 13-16th, 2023; Virtual) Date/Time: February 14, 2023 10:40 a.m. ET Webcast: https://wsw.com/webcast/svb8/register.aspx?conf=svb8&page=amrn&url=https://wsw.com/webcast/svb8/am

Advertisement
Advertisement